Predicting the Role of DNA Polymerase β Alone or with <i>KRAS</i> Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy

Predicting the Role of DNA Polymerase β Alone or with <i>KRAS</i> Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy

Clinical data suggest that only a subgroup of non-small cell lung cancer (NSCLC) patients has long-term benefits after front-line platinum-based therapy. We prospectively investigate whether KRAS status and DNA polymerase β expression could help identify patients responding to platinum compounds. Pr...

Full description

Bibliographic Details
Main Authors: Maria Francesca Alvisi, Monica Ganzinelli, Helena Linardou, Elisa Caiola, Giuseppe Lo Russo, Fabiana Letizia Cecere, Anna Cecilia Bettini, Amanda Psyrri, Michele Milella, Eliana Rulli, Alessandra Fabbri, Marcella De Maglie, Pierpaolo Romanelli, Samuel Murray, Gloriana Ndembe, Massimo Broggini, Marina Chiara Garassino, Mirko Marabese
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Journal of Clinical Medicine
Subjects:
NSCLC
KRAS
DNA polymerase beta
platinum-based first-line
Online Access:https://www.mdpi.com/2077-0383/9/8/2438

Internet

https://www.mdpi.com/2077-0383/9/8/2438

Similar Items